Aclarion, Inc. (ACON)
| Market Cap | 6.49M |
| Revenue (ttm) | 49,901 |
| Net Income (ttm) | -9.41M |
| Shares Out | 7.82M |
| EPS (ttm) | -7.12 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 74,160 |
| Open | 0.720 |
| Previous Close | 0.600 |
| Day's Range | 0.630 - 0.847 |
| 52-Week Range | 0.380 - 4.050 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 3.06 (+282.5%) |
| Earnings Date | n/a |
About ACON
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ACON stock is "Buy." The 12-month stock price forecast is $3.06, which is an increase of 282.50% from the latest price.
News
Gregory Basil MD to Join Aclarion as a Key Opinion Leader Surgeon Advisor
Broomfield, CO, Jan. 31, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),a healthcare technology company that is leveraging biomarkers ...
Aclarion Appoints George Frey MD as Seventh Key Opinion Leader Surgeon Advisor
Broomfield, CO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers ...
Aclarion to Present at the Jan 26th Virtual Investor Summit Microcap Event
Broomfield, Colorado--(Newsfile Corp. - January 17, 2023) - Aclarion, Inc., (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers...
Dr. Christopher Ames to Join Aclarion as a Key Opinion Leader Surgeon Advisor
Broomfield, CO, Dec. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarke...
Aclarion's Key Opinion Leader Program Adds Fifth Surgeon Advisor with Addition of Eric Potts, MD
Development of this program supports Aclarion's commitment to lead with strong clinical evidence and engage the payer community through key opinion leader advocacy.
Aclarion Adds to Growing Key Opinion Leader Program with Juan Uribe M.D. as a Surgeon Advisor
Development of this program supports Aclarion's commitment to lead with strong clinical evidence and engage the payer community through key opinion leader advocacy.
Aclarion Adds to Strong Patent Portfolio with Notice of Allowance for New U.S. Patent Application Addressing Key Pain Indicator Biomarker
Strengthens portfolio by addressing the anaerobic bacteria that can seed into the intervertebral disc, proliferate, and accelerate painful disc degeneration.
Aclarion, Inc. Releases Updated Investor Presentation In Connection with Appearance at LD Micro Main Event XV
BROOMFIELD, CO / ACCESSWIRE / October 25, 2022 / Aclarion, Inc. (NASDAQ:ACON)(NASDAQ:ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers and proprietary...
Dr. Sigurd Berven to join Aclarion as a Key Opinion Leader Surgeon Advisor
BROOMFIELD, CO / ACCESSWIRE / October 24, 2022 / Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augm...
Aclarion To Present at The LD Micro Main Event XV
Presentation on Tuesday, October 25th at 9:00 AM PTBroomfield, Colorado--(Newsfile Corp. - October 12, 2022) - Aclarion, Inc., (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcar...
Aclarion Announces Participation at the NASS 37th Annual Meeting
Nociscan utilized within unprecedented NIH HEAL Initiative featured at NASS 2022 NociscanTM is the first evidence-supported SaaS platform to objectively analyze intradiscal pain Nociscan bridges major...
John Keller M.D. to Join Aclarion as a Key Opinion Leader Surgeon Advisor
Aclarion Key Opinion Leader program supports focused strategy of building strong clinical evidence and payer community advocacy to drive adoption of NociscanTM solution BROOMFIELD, CO / ACCESSWIRE / O...
Nociscan Selected for Inclusion in Pivotal National Institutes of Health (NIH) Study for Low Back Pain
NIH funded Biomarkers for Evaluating Spine Treatments (BEST) Trial launching this quarter BEST to study the role of biomarkers in optimizing the treatment of chronic low back pain NociscanTM to be com...
Aclarion, Inc. to Present at Investor Summit Group's Q3 Virtual Conference
Broomfield, Colorado--(Newsfile Corp. - August 4, 2022) - Aclarion, Inc. (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcare technology company that is leveraging biomarkers and...
Aclarion Announces Start of Healthcare Economic Analysis Study to Evaluate Financial Impact of Nociscan
Initial findings from the EVAL study are expected to be released in Q4 2022 Study initiated to assess impact of Nociscan on the cost of care for chronic low back pain (CLBP) patients Promising initial...
Aclarion to Present 2-year Follow Up Data on Pivotal Clinical Trial Linking Nociscan to Better Surgical Outcomes for Discogenic Low Back Pain
Superior Clinical Outcomes for NociscanTM Proving to be Durable at Two Years Two Year Results and the Schedule of Future Clinical Trials to be Outlined at the Annual State of Spine Surgery Think Tank ...